PeptideStack
5.2kquestions
20kanswers
220users

How do I compare SSA and CPC on lead time to Sweden?

Asked 1 Dec 2025Modified 6 months agoViewed 15k times
22

What I am working with: SSA · CPC · Sweden.

I am trying to choose between two options that are usually discussed as though only one exists.

I am not optimising for price, but I am not indifferent to it either.

So which one, and on what grounds?

vendor-comparison
vendor-comparison

Side-by-side comparison of suppliers on measurable axes - independently confirmed purity and content, lead time, cold-chain handling,…

388 questions
international-shipping
international-shipping

Cross-border movement of research material: transit lanes and their thermal profiles, tracked versus untracked, declaration accuracy, and what…

471 questions
cold-chain
cold-chain

Keeping material within a temperature window from manufacture to use: phase-change packs versus dry ice, thermal mass, transit-lane temperature…

578 questions
shareeditfollowflag
OS
askedorla_sheridan18k271 Dec 2025
3Voting to keep this open — it is more specific than it first looks. – felix_araya 3 months ago
add a comment

5 Answers

Accepted answer first, then by votes
21

Accepted answer

Ratings on this site are ours alone and are deliberately not reconciled with anyone else's.

Cost per milligram of actual peptide is the honest price comparison, which means dividing by measured content rather than by label claim.

Cost per milligram, adjusted honestly

StepValueNote
Vial price, 10 mg nominal£34.00As advertised
Nominal cost per mg£3.4034 ÷ 10
Measured content9.2 mgIndependent content assay
Cost per actual mg£3.7034 ÷ 9.2
Dead-space loss, 20 draws4 %80 µL of a 2 mL fill
Cost per delivered mg£3.853.70 ÷ 0.96
First vial, with £110 assay£14.85Testing dominates a single vial

Lead time and lane behaviour are supplier properties too and are easier to compare than analytical ones, because they need no laboratory at all.

Content assay results across the published datasets vary considerably more between suppliers than purity does, which makes content the more discriminating axis.

Comparisons drawn from different laboratories at different times are weaker evidence than most people treat them as.

One laboratory, one method, one submission. Otherwise it is not a comparison.

edited 25 Jan 2026 by ines_brandt — clarified the distinction between purity and content

shareimprove this answerflag
IB
answered · acceptedines_brandt113k2572 Jan 2026
8Adding for future readers: ask for the lot-specific certificate before ordering, not after. – Dr_Tomas_Kral 25 days ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
24

Answering this needs the axis. A supplier that is best on paperwork and a supplier that is best on price are both correct answers to different questions.

To compare properly: order the same compound at the same nominal strength from each supplier, submit all samples to the same laboratory in the same submission if possible, and ask for the same test set on each.

Publish the method with the result. A comparison without the laboratory named and the submission dates given is not reproducible by anyone.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Price per milligram of measured peptide, not per milligram of label claim.

shareimprove this answerflag
LT
answeredlane_transit60k4724 Jan 2026
17

The relevant point is that two competent laboratories disagree by half a per cent on identical material, which is larger than most of the differences people argue about.

Content is the more discriminating measurement than purity for supplier comparison, because purity clusters tightly among competent suppliers and content does not.

In practice, submitting to different laboratories introduces a method difference that commonly exceeds the supplier difference. Gradient slope alone can move a reported purity figure by a per cent in either direction.

The ratings on this site are a community opinion average on a ten-point scale and are not reconciled with any other community's figures.

The caveat is that a comparison is a snapshot of the lots compared, and lots change.

Use a fixed documentation checklist rather than an impression.

shareimprove this answerflag
MO
answeredmarta_okonkwo190k25813 Jan 2026
10

The honest answer is that most claimed differences between reputable suppliers are inside inter-laboratory noise.

Sample size matters. One order each is an anecdote about six vials; three orders each over a year is the beginning of a comparison.

No supplier on this site pays for its position, and the storefront links are marked nofollow and sponsored.

Compare content, not purity. Purity clusters and content does not.

shareimprove this answerflag
M4
answeredmz_4113101k35810 Dec 2025
9

The short version: same compound, same laboratory, same method, ideally same week — otherwise you are comparing laboratories rather than suppliers.

Compare documentation on a fixed checklist rather than by impression: lot specificity, method section, chromatogram availability, quantified content, water and counter-ion figures, and whether the code is on the vial.

Inter-laboratory spread on identical peptide material is routinely half a per cent to a per cent by RP-HPLC, which is the noise floor for any cross-laboratory comparison.

Name the laboratory and the dates or the comparison cannot be reproduced.

shareimprove this answerflag
WO
answeredw_okoye43k13722 Dec 2025
4Worth flagging that comparing across laboratories is comparing laboratories, not suppliers. – deamidation_watch 4 months ago
5I would add a line about writing the accept threshold down first. It is the step everyone skips. – nominal_ten 6 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.